Agenus (AGEN) Competitors $4.05 +0.08 (+2.02%) Closing price 04:00 PM EasternExtended Trading$4.05 0.00 (0.00%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. RIGL, EBS, XOMA, VNDA, CDXS, IRWD, CBIO, SGMO, ACHV, and DOMHShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Crescent Biopharma (CBIO), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), and Dominari (DOMH). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Crescent Biopharma Sangamo Therapeutics Achieve Life Sciences Dominari Agenus (NASDAQ:AGEN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Do analysts rate AGEN or RIGL? Agenus presently has a consensus price target of $14.50, indicating a potential upside of 258.02%. Rigel Pharmaceuticals has a consensus price target of $38.20, indicating a potential upside of 42.38%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Rigel Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Is AGEN or RIGL more profitable? Rigel Pharmaceuticals has a net margin of 36.51% compared to Agenus' net margin of -167.52%. Rigel Pharmaceuticals' return on equity of 438.89% beat Agenus' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-167.52% N/A -81.04% Rigel Pharmaceuticals 36.51%438.89%57.03% Which has more risk & volatility, AGEN or RIGL? Agenus has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Which has stronger earnings & valuation, AGEN or RIGL? Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$103.46M1.25-$227.21M-$7.15-0.57Rigel Pharmaceuticals$267.92M1.80$17.49M$5.414.96 Does the media prefer AGEN or RIGL? In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Agenus. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 5 mentions for Agenus. Agenus' average media sentiment score of 0.69 beat Rigel Pharmaceuticals' score of 0.26 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in AGEN or RIGL? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 5.5% of Agenus shares are owned by insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRigel Pharmaceuticals beats Agenus on 12 of the 15 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.03M$3.33B$6.04B$10.46BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-0.5722.2285.3127.07Price / Sales1.25438.60586.80189.44Price / CashN/A44.9825.7330.17Price / Book-0.3110.3812.666.69Net Income-$227.21M-$52.31M$3.31B$276.03M7 Day Performance-2.41%0.59%-0.44%-1.14%1 Month Performance-9.60%13.90%8.70%6.49%1 Year Performance-10.60%28.95%76.79%34.44% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.1744 of 5 stars$4.05+2.0%$14.50+258.0%-12.4%$129.03M$103.46M-0.57440RIGLRigel Pharmaceuticals3.6726 of 5 stars$28.90+1.3%$38.20+32.2%+82.6%$518.47M$179.28M5.34160EBSEmergent Biosolutions4.3054 of 5 stars$9.16+0.1%$13.50+47.4%+3.7%$488.70M$812.50M3.742,420XOMAXOMA Royalty4.094 of 5 stars$36.61-7.8%$69.50+89.8%+32.0%$442.54M$12.77M-23.6210VNDAVanda Pharmaceuticals4.0953 of 5 stars$5.40-0.6%$16.50+205.6%+19.6%$319.08M$203.47M-4.78290CDXSCodexis3.0384 of 5 stars$2.69+5.9%$11.00+308.9%-17.8%$242.83M$59.35M-3.24250IRWDIronwood Pharmaceuticals4.4427 of 5 stars$1.48-4.5%$4.94+233.8%-62.8%$240.40M$351.41M-29.59220Positive NewsGap UpCBIOCrescent Biopharma4.1667 of 5 stars$11.60-1.0%$25.60+120.7%N/A$226.78M$10K-0.3350SGMOSangamo Therapeutics2.0612 of 5 stars$0.70+2.4%$4.50+543.8%-19.7%$210.90M$57.80M-2.41480Gap UpACHVAchieve Life Sciences2.5958 of 5 stars$3.16+0.3%$12.00+279.7%-38.4%$161.49MN/A-2.1620DOMHDominari0.6226 of 5 stars$7.42+1.8%N/A+205.3%$115.34M$52.81M-3.134Gap Up Related Companies and Tools Related Companies Rigel Pharmaceuticals Alternatives Emergent Biosolutions Alternatives XOMA Royalty Alternatives Vanda Pharmaceuticals Alternatives Codexis Alternatives Ironwood Pharmaceuticals Alternatives Crescent Biopharma Alternatives Sangamo Therapeutics Alternatives Achieve Life Sciences Alternatives Dominari Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
